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Does Cardiac Sympathetic Innervation Imaging Fulﬁll
an Unmet Need for Managing Atrial Fibrillation?*
Michael H. Crawford, MD
San Francisco, CaliforniaMeta-iodobenzylguanidine (mIBG) is a structural
analog of guanethidine that shares the same uptake
and storage mechanisms as norepinephrine in nerve
endings. By radiolabeling mIBG with iodine-123,
the uptake and storage of mIBG can be imaged
with a gamma camera. Because mIBG is not me-
tabolized, its accumulation over several hours is a
measure of neuronal integrity. mIBG was first used
for myocardial imaging in 1987, but in the ensuing
20 years, it has not established a clinical role in
cardiac imaging.
See page 78
Recently, mIBG imaging has been employed in
studies of heart failure patients. Heart failure is
associated with high sympathetic activity mani-
fested in part by increased release of norepineph-
rine. That leads to a decrease in neuronal norepi-
nephrine reuptake due to post-transcriptional
down-regulation of the cardiac norepinephrine
transporter. This increase in adrenergic nervous
system activity of the heart is exhibited as de-
creased mIBG uptake relative to a background
standard of the upper mediastinum or the heart/
mediastinum ratio (H/M). In a recent report from
the ADMIRE-HF (AdreViewMyocardial Imaging
for Risk Evaluation in Heart Failure) study, a
decrease in H/M was associated with the composite
end point of heart failure progression, ventricular
tachyarrhythmias, and death (1). Also, H/M was an
independent predictor by multivariate analysis, add-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Division of Cardiology, Department of Medicine, University of
California San Francisco, San Francisco, California. The author has
reported that he has no relationships to disclose.ing to information obtained from brain natriuretic
peptide (BNP), ejection fraction, and New York
Heart Association functional class. That led the
investigators to speculate that mIBG imaging may
have a role in the management of heart failure
patients.
In this issue of iJACC, there is a report by Akutsu
et al. (2) of a study of mIBG imaging in 98 patients
with paroxysmal atrial fibrillation, with relatively
normal left ventricular systolic function and without
symptoms of heart failure. They hypothesized that
a reduced H/M would predict the development of
heart failure and permanent atrial fibrillation (AF).
They showed that a low H/M was a powerful
independent predictor of the development of per-
manent AF alone and heart failure plus permanent
AF. They concluded that increased adrenergic ner-
vous system activity is associated with the develop-
ment of permanent AF and heart failure in subjects
with paroxysmal AF and no heart failure. Also, they
suggested that mIBG may be useful for managing
patients with paroxysmal AF.
Perhaps the most important contribution of this
paper is the demonstration that increased cardiac
sympathetic nervous system activity is related to the
development of permanent AF. We know clinically
that conditions associated with increased adrenergic
activity, such as exercise, stress, and excess alcohol
consumption, can be temporally related to the onset
of AF, but little proof of the role of adrenergic
activity exists. Also, we know that heart failure is
associated with increased sympathetic activity.
Thus, it is not surprising that the development of
AF and heart failure were related to sympathetic
activity in this study, and mIBG was an elegant way
to document this relationship.
In this study, mIBG was the strongest predictor
of AF and heart failure by multivariate analysis.
However, left ventricular ejection fraction (LVEF)
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Crawford
Editorial Comment
88as also independently predictive of these events,
nd BNP predicted the development of permanent
F and heart failure. When the occurrence of heart
ailure and AF were examined by sensitivity, spec-
ficity, and receiver-operator characteristic curve
reas, there was little difference in the predictive
ower of mIBG, LVEF, and BNP. In fact, for
redicting death alone in a Kaplan-Meier analysis,
NP was best. Both BNP and mIBG have a
elatively low specificity for predicting permanent
F and heart failure, so their positive predictive
alue is low. Conversely, their relatively high sen-
itivities mean that they are most useful when
ormal. This limits their role in therapeutic decisions.
The ability of LVEF to predict permanent AF is
nteresting since it was truncated at 50% in the
election criteria for the study. Echocardiography
as used to assess LVEF for study entry, and
atients with a value 50% were excluded. A value
f 50% is just below the lower limit of normal of
5% by the American Society of Echocardiography
riteria (3). Perhaps if patients with lower LVEF
ut no heart failure symptoms were allowed in the
tudy, LVEF would have been more strongly pre-
ictive. Clearly, mIBG is a stronger predictor of
ermanent AF in patients with relatively normal
VEF.
There are many risk factors for the development
f AF, yet it is clinically difficult to predict who will
et permanent AF. In this study, the usual clinical
ractice of cardioversion and drug therapy were
mployed to keep patients in sinus rhythm if they
elapsed, but nothing special was done for patients
ho did not relapse. The results of this study
uggest that a low H/M in a paroxysmal AF patient
hould encourage prophylactic therapy, perhapsing the development of atrial fibrilla- al. European ancestryevelopment of permanent AF. We would need a
andomized trial to establish such a strategy, but pre-
enting permanent AF would certainly be desirable.
Because most of the patients in this study had
Fs in the normal range (55%), it is likely that
any of those who had heart failure had diastolic
V dysfunction. Diastolic parameters were not
rovided for the patients. That raises the question
f whether such measures might also be predictive
f the development of permanent AF and heart
ailure. If so, echocardiography is less expensive and
oes not involve radiation exposure in comparison
ith mIBG. Also, we may be on the verge of the
linical application of genetics to AF risk. Atrial
brillation clearly has a genetic component and is
uch more prevalent among white Americans than
mong black Americans, despite a higher preva-
ence of more traditional AF risk factors among
lacks (4). Whether mIBG will be useful in more
acially diverse populations is unclear.
Finally, a barrier to the widespread application of
IBG imaging for the assessment of patients with
aroxysmal AF is a lack of standardization of the
echnique between laboratories. Recently, Europe-
ns have suggested a standardized technique, but it
as not been widely accepted at this point (5).
opefully, the American Society of Nuclear Car-
iology will address this soon, as cardiac mIBG may
e on the threshold of more wide utilization as our
ging population is increasing the prevalence of AF
nd heart failure.
eprint requests and correspondence: Dr. Michael H.
rawford, 505 Parnassus Avenue, Box 0124, San Fran-
isco, California 94143. E-mail: crawfordm@medicine.with at least beta-blockers to try to prevent the ucsf.edu.5
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